1. In severe alcoholic hepatitis, oral prednisolone is the preferred corticosteroid rather than prednisone. Which property of prednisolone best explains this preference in a patient with significant hepatic dysfunction?
A) Prednisolone has a longer plasma half-life, allowing once-weekly dosing
B) Prednisolone is renally activated, bypassing the failing liver
C) Prednisolone is the already-active compound and does not require hepatic conversion, unlike prednisone
D) Prednisolone has no mineralocorticoid activity, eliminating fluid retention
E) Prednisolone is not metabolized by cytochrome P450 enzymes
ANSWER: C
Rationale:
Prednisone is a prodrug that must undergo hepatic 11-beta-hydroxysteroid dehydrogenase conversion to its active form prednisolone; in significant hepatic dysfunction this activation step may be impaired, so administering the already-active prednisolone removes the dependence on a compromised liver.
Option A: Option A is incorrect because prednisolone is dosed daily (40 mg/day for 28 days), not weekly, and the preference has nothing to do with an extended half-life.
Option B: Option B is incorrect because prednisolone is not renally activated; the relevant activation step that prednisone requires occurs in the liver, and prednisolone simply bypasses the need for it.
Option D: Option D is incorrect because prednisolone retains some mineralocorticoid activity and does not eliminate fluid retention; this is not the basis for the preference.
Option E: Option E is incorrect because corticosteroids are metabolized through hepatic pathways, and the preference rests on avoiding the activation step, not on escaping cytochrome P450 metabolism.
2. Corticosteroids reduce mortality in severe alcoholic hepatitis by dampening the systemic inflammatory response. Which molecular action best accounts for this anti-inflammatory effect?
A) Inhibition of NF-kappaB (nuclear factor kappa-B)-mediated transcription of pro-inflammatory cytokines such as tumor necrosis factor and interleukin-8
B) Direct neutralization of circulating ammonia in the portal blood
C) Agonism at the farnesoid X receptor to suppress bile acid synthesis
D) Competitive displacement of hydrophobic bile acids from the bile acid pool
E) Selective agonism at the hepatic thyroid hormone receptor-beta
ANSWER: A
Rationale:
Corticosteroids suppress the inflammatory cascade driving alcoholic hepatitis by inhibiting NF-kappaB-mediated transcription of pro-inflammatory cytokines including tumor necrosis factor and interleukin-8, which reduces hepatocyte apoptosis and necroinflammation.
Option B: Option B is incorrect because neutralizing portal ammonia is not a corticosteroid action; ammonia-directed therapy in liver disease involves lactulose and rifaximin in hepatic encephalopathy.
Option C: Option C is incorrect because farnesoid X receptor agonism describes obeticholic acid in cholestatic disease, not the mechanism of corticosteroids.
Option D: Option D is incorrect because displacing hydrophobic bile acids describes ursodeoxycholic acid, not a glucocorticoid effect.
Option E: Option E is incorrect because thyroid hormone receptor-beta agonism describes resmetirom in MASH and is unrelated to corticosteroid anti-inflammatory activity.
3. A hepatologist is considering resmetirom for a patient with MASH (metabolic dysfunction-associated steatohepatitis). Which statement most precisely describes its approved indication and a key limitation?
A) It is approved for all stages of MASH including compensated and decompensated cirrhosis
B) It is approved only for simple steatosis without steatohepatitis or fibrosis
C) It is approved for decompensated cirrhosis but not for earlier fibrosis stages
D) It is approved regardless of fibrosis stage and requires no liver function monitoring
E) It is approved for MASH with moderate-to-severe fibrosis (stages F2 to F3) and is not approved for cirrhosis (F4); it should be avoided in Child-Pugh B or C
ANSWER: E
Rationale:
Resmetirom is indicated for MASH with moderate-to-severe fibrosis, stages F2 to F3, confirmed by biopsy or non-invasive assessment; it is not approved for compensated or decompensated cirrhosis (F4) and should be avoided in Child-Pugh B or C disease, with liver function monitored at baseline, 3 months, and 6 months.
Option A: Option A is incorrect because cirrhosis, particularly decompensated cirrhosis, is outside the approved indication.
Option B: Option B is incorrect because simple steatosis without steatohepatitis or significant fibrosis is not the target population; the indication requires F2 to F3 fibrosis.
Option C: Option C inverts the indication, since the drug is approved for F2 to F3 fibrosis and not for cirrhosis.
Option D: Option D is incorrect because the indication is fibrosis-stage specific and liver function monitoring is required, not waived.
4. Resmetirom is engineered as a selective thyroid hormone receptor-beta agonist. Why does receptor-beta selectivity matter clinically?
A) Receptor-beta is the predominant isoform in cardiac muscle, so selectivity maximizes inotropy
B) Receptor-beta predominates in the liver, so selective agonism drives hepatic fatty acid oxidation and lipid lowering while sparing the cardiac and skeletal effects mediated by receptor-alpha
C) Receptor-beta selectivity allows the drug to act as a farnesoid X receptor agonist in the gut
D) Receptor-beta is absent from the liver, so the drug acts only on adipose tissue
E) Receptor-beta selectivity eliminates the need for any low-density lipoprotein monitoring
ANSWER: B
Rationale:
Thyroid hormone receptor-beta is the predominant isoform in the liver, so selective receptor-beta agonism increases hepatic fatty acid oxidation, reduces lipogenesis, and lowers low-density lipoprotein cholesterol while avoiding the thyrotoxic cardiac and skeletal effects driven by receptor-alpha activation.
Option A: Option A is incorrect because receptor-alpha, not receptor-beta, predominates in cardiac muscle, and the goal of selectivity is to avoid cardiac stimulation, not maximize inotropy.
Option C: Option C is incorrect because receptor-beta selectivity concerns the thyroid hormone receptor and has nothing to do with farnesoid X receptor agonism.
Option D: Option D is incorrect because receptor-beta is in fact the dominant hepatic isoform, which is precisely why the liver is the principal site of action.
Option E: Option E is incorrect because the drug produces a pharmacodynamic reduction in low-density lipoprotein cholesterol, and receptor selectivity does not remove monitoring considerations.
5. Pioglitazone improves hepatic histology in MASH. Which description most precisely captures its mechanism in this setting?
A) It directly inhibits hepatic de novo lipogenesis through cytochrome P450 blockade
B) It is a thyroid hormone receptor-beta agonist that increases hepatic fatty acid oxidation
C) It sequesters bile acids in the intestinal lumen to interrupt enterohepatic recycling
D) It is a peroxisome proliferator-activated receptor-gamma agonist that improves insulin sensitivity in adipose tissue, reducing free fatty acid flux to the liver and decreasing hepatic de novo lipogenesis
E) It is a glucagon-like peptide-1 receptor agonist that lowers weight and hepatic fat delivery
ANSWER: D
Rationale:
Pioglitazone is a peroxisome proliferator-activated receptor-gamma agonist that improves insulin sensitivity primarily in adipose tissue, reducing free fatty acid flux to the liver and decreasing hepatic de novo lipogenesis, which underlies its histological benefit in steatohepatitis.
Option A: Option A is incorrect because pioglitazone does not act by cytochrome P450 blockade; its effect is receptor-mediated insulin sensitization.
Option B: Option B is incorrect because thyroid hormone receptor-beta agonism describes resmetirom, not pioglitazone.
Option C: Option C is incorrect because bile acid sequestration describes cholestyramine and is unrelated to pioglitazone.
Option E: Option E is incorrect because glucagon-like peptide-1 receptor agonism describes semaglutide, a different class with a distinct mechanism.
6. Ursodeoxycholic acid is first-line for primary biliary cholangitis. Which description most precisely characterizes its principal cytoprotective mechanism?
A) As a hydrophilic bile acid, it competitively displaces toxic hydrophobic bile acids such as chenodeoxycholic and deoxycholic acid from the bile acid pool, reducing their cytotoxicity to cholangiocytes
B) It is a farnesoid X receptor agonist that suppresses CYP7A1 (cholesterol 7-alpha-hydroxylase) to halt all bile acid synthesis
C) It activates peroxisome proliferator-activated receptor-alpha to upregulate bile acid transporters
D) It is a hydrophobic bile acid that increases the cytotoxic bile acid load to stimulate ductular regeneration
E) It binds bile acids in the gut lumen, acting purely as an intestinal sequestrant
ANSWER: A
Rationale:
Ursodeoxycholic acid is a hydrophilic bile acid that competitively displaces toxic hydrophobic bile acids, particularly chenodeoxycholic and deoxycholic acid, from the bile acid pool, reducing their cytotoxic effect on cholangiocytes, with additional direct cytoprotective, anti-apoptotic, and immunomodulatory actions on biliary epithelium.
Option B: Option B is incorrect because farnesoid X receptor agonism with CYP7A1 suppression describes obeticholic acid, not ursodeoxycholic acid.
Option C: Option C is incorrect because peroxisome proliferator-activated receptor-alpha activation describes bezafibrate.
Option D: Option D inverts the pharmacology, because ursodeoxycholic acid is hydrophilic and reduces, rather than increases, the cytotoxic bile acid load.
Option E: Option E is incorrect because ursodeoxycholic acid is an orally absorbed bile acid that enters the bile acid pool, not a non-absorbed luminal sequestrant like cholestyramine.
7. Obeticholic acid is used as second-line therapy in primary biliary cholangitis. Which mechanism most precisely describes how it reduces the enterohepatic bile acid burden?
A) It is a hydrophilic bile acid that displaces hydrophobic bile acids from the pool
B) It blocks the farnesoid X receptor, thereby increasing bile acid synthesis
C) It is a farnesoid X receptor agonist that suppresses bile acid synthesis by downregulating CYP7A1 (cholesterol 7-alpha-hydroxylase) and upregulates ileal bile acid binding protein
D) It is a non-absorbable disaccharide that acidifies the colon to trap bile acids
E) It inhibits cytochrome P450 3A4 to slow hepatic bile acid clearance
ANSWER: C
Rationale:
Obeticholic acid is a potent synthetic bile acid analogue and farnesoid X receptor agonist; activating the receptor in hepatocytes and enterocytes suppresses bile acid synthesis by downregulating CYP7A1, the rate-limiting enzyme of the classic synthesis pathway, and upregulates ileal bile acid binding protein, together reducing the enterohepatic bile acid burden.
Option A: Option A is incorrect because displacing hydrophobic bile acids describes ursodeoxycholic acid, not the receptor-mediated action of obeticholic acid.
Option B: Option B inverts the pharmacology, since obeticholic acid is a farnesoid X receptor agonist that suppresses, rather than a blocker that increases, bile acid synthesis.
Option D: Option D is incorrect because acidifying the colon describes lactulose and has no role in bile acid handling here.
Option E: Option E is incorrect because the effect arises from farnesoid X receptor agonism, not cytochrome P450 3A4 inhibition.
8. A patient on obeticholic acid for primary biliary cholangitis shows a rise in gamma-glutamyl transferase (GGT). Which interpretation is correct, and what is the key safety boundary for this drug?
A) The GGT rise signals acute hepatotoxicity and the drug must be stopped immediately in all patients
B) The GGT rise indicates treatment failure and warrants switching to ursodeoxycholic acid alone
C) The GGT rise reflects worsening pruritus and is unrelated to the drug
D) The GGT rise mandates immediate liver transplantation regardless of clinical status
E) The GGT rise is an expected pharmacodynamic effect and does not indicate hepatotoxicity, but obeticholic acid is contraindicated in decompensated cirrhosis (Child-Pugh B or C) because of a risk of hepatic decompensation
ANSWER: E
Rationale:
A rise in gamma-glutamyl transferase with obeticholic acid is an expected pharmacodynamic effect and does not by itself indicate hepatotoxicity; the critical safety boundary is that the drug is contraindicated in decompensated cirrhosis (Child-Pugh B or C) because post-marketing data reported a risk of hepatic decompensation.
Option A: Option A is incorrect because an isolated expected GGT rise is not a marker of acute hepatotoxicity requiring universal discontinuation.
Option B: Option B is incorrect because the GGT change does not denote treatment failure, and the management issue is the cirrhosis contraindication rather than reverting to monotherapy.
Option C: Option C is incorrect because the GGT elevation is a pharmacodynamic effect, not a manifestation of pruritus.
Option D: Option D is incorrect because an expected enzyme change does not by itself indicate transplantation.
9. Bezafibrate is a third-line option in primary biliary cholangitis. Which statement most precisely pairs its mechanism with a monitoring requirement?
A) It is a farnesoid X receptor agonist, and monitoring focuses on serum thyroid hormone levels
B) It is a peroxisome proliferator-activated receptor-alpha agonist that suppresses bile acid synthesis and upregulates bile acid transporters; renal function must be monitored, and myopathy risk rises with statin co-administration
C) It is a hydrophilic bile acid, and the chief monitoring concern is serum calcium
D) It is a non-absorbable antibiotic, and monitoring centers on stool frequency
E) It is a thyroid hormone receptor-beta agonist, and monitoring centers on cardiac inotropy
ANSWER: B
Rationale:
Bezafibrate is a fibric acid derivative that activates peroxisome proliferator-activated receptor-alpha; in primary biliary cholangitis this suppresses bile acid synthesis and upregulates bile acid transporters, and because fibrates can raise creatinine and increase myopathy risk with statins, renal function and statin co-administration must be monitored.
Option A: Option A is incorrect because bezafibrate is not a farnesoid X receptor agonist, and thyroid hormone monitoring is not its concern.
Option C: Option C is incorrect because bezafibrate is not a bile acid, and calcium is not the relevant monitoring parameter.
Option D: Option D is incorrect because bezafibrate is not an antibiotic, so stool frequency is not the monitoring focus.
Option E: Option E is incorrect because thyroid hormone receptor-beta agonism describes resmetirom, and cardiac inotropy is not a bezafibrate monitoring parameter.
10. A trainee proposes high-dose ursodeoxycholic acid at 28 to 30 mg/kg/day for a patient with primary sclerosing cholangitis. Which statement correctly characterizes this approach?
A) It is the proven standard of care and improves transplant-free survival
B) It is equivalent to standard-dose ursodeoxycholic acid in both efficacy and safety
C) It is preferred over endoscopic management of dominant strictures
D) It was associated with increased adverse events in a randomized trial and is actively contraindicated; standard-dose ursodeoxycholic acid has not been shown to improve PSC outcomes either
E) It reliably reverses biliary fibrosis when started early
ANSWER: D
Rationale:
High-dose ursodeoxycholic acid at 28 to 30 mg/kg/day was associated with increased adverse events in a large randomized trial in primary sclerosing cholangitis and is actively contraindicated, and even standard-dose ursodeoxycholic acid has not been shown to improve outcomes in adequately powered PSC trials.
Option A: Option A is incorrect because high-dose therapy is not standard of care and does not improve transplant-free survival; no agent has proven disease-modifying benefit in PSC.
Option B: Option B is incorrect because high-dose therapy is not equivalent in safety, having caused increased adverse events.
Option C: Option C is incorrect because endoscopic dilation or short-term stenting of dominant strictures is a recognized management priority, whereas high-dose ursodeoxycholic acid is harmful.
Option E: Option E is incorrect because no ursodeoxycholic acid regimen reliably reverses biliary fibrosis in PSC.
11. Which statement most precisely describes the established role of rifaximin in hepatic encephalopathy?
A) It is indicated as add-on therapy to lactulose for secondary prophylaxis of overt encephalopathy recurrence, not as a monotherapy replacement for lactulose
B) It is first-line monotherapy that should replace lactulose at diagnosis
C) It is used only for minimal hepatic encephalopathy and has no role after an overt episode
D) It is a systemic antibiotic whose efficacy depends on high blood levels
E) It is an osmotic laxative that acidifies the colon to trap ammonia
ANSWER: A
Rationale:
Rifaximin is indicated as add-on therapy to ongoing lactulose for secondary prophylaxis of overt hepatic encephalopathy recurrence; the combination is superior to either agent alone and rifaximin is not a monotherapy replacement for lactulose.
Option B: Option B is incorrect because rifaximin is not first-line monotherapy and does not replace lactulose at diagnosis.
Option C: Option C is incorrect because its principal evidence-based role is precisely after an overt episode, for secondary prophylaxis, rather than being limited to minimal encephalopathy.
Option D: Option D is incorrect because rifaximin has systemic bioavailability under 0.4 percent and works within the gut lumen, not through high blood levels.
Option E: Option E is incorrect because acidifying the colon to trap ammonia describes lactulose; rifaximin is a gut-restricted antibiotic.
12. Zinc supplementation is sometimes used as an adjunct in hepatic encephalopathy. Which mechanism best explains the rationale for correcting zinc deficiency in cirrhosis?
A) Zinc directly acidifies the colon to convert ammonia to ammonium
B) Zinc is a non-absorbed antibiotic that suppresses urease-producing bacteria
C) Zinc is an essential cofactor for urea cycle enzymes such as ornithine carbamoyltransferase and argininosuccinate synthetase, so depletion impairs hepatic ammonia disposal
D) Zinc chelates ammonia in the systemic circulation for renal excretion
E) Zinc blocks ammonia transport across the blood-brain barrier
ANSWER: C
Rationale:
Zinc is an essential cofactor for urea cycle enzymes including ornithine carbamoyltransferase and argininosuccinate synthetase, so the zinc depletion that is common in cirrhosis impairs hepatic ammonia disposal capacity, providing the rationale for supplementation as an adjunct.
Option A: Option A is incorrect because colonic acidification describes lactulose, not a zinc effect.
Option B: Option B is incorrect because suppressing urease-producing bacteria describes rifaximin; zinc is not an antibiotic.
Option D: Option D is incorrect because zinc does not chelate circulating ammonia for renal excretion.
Option E: Option E is incorrect because zinc does not block blood-brain barrier ammonia transport; its role is enzymatic support of ammonia metabolism.
13. In the stepwise management of cholestatic pruritus, which statement most precisely characterizes rifampicin?
A) It is the first-line agent and works by sequestering luminal bile acids
B) It is a fourth-line agent acting as a selective serotonin reuptake inhibitor
C) It is a third-line agent acting through central opioid antagonism
D) It is the first-line agent acting through farnesoid X receptor agonism
E) It is a second-line agent that acts by pregnane X receptor-mediated upregulation of bile acid detoxification and requires monthly liver test monitoring for idiosyncratic hepatotoxicity
ANSWER: E
Rationale:
Rifampicin is the second-line agent for cholestatic pruritus, acting through pregnane X receptor-mediated upregulation of bile acid detoxification pathways, and because of a risk of idiosyncratic hepatotoxicity it requires monthly liver test monitoring.
Option A: Option A is incorrect because the first-line agent is cholestyramine, which sequesters luminal bile acids; rifampicin is second-line and works by a different mechanism.
Option B: Option B is incorrect because the selective serotonin reuptake inhibitor used here is sertraline, a fourth-line option, not rifampicin.
Option C: Option C is incorrect because central opioid antagonism describes naltrexone, the third-line agent.
Option D: Option D is incorrect because rifampicin is not first-line and does not act through farnesoid X receptor agonism.
14. Before initiating prednisolone in severe alcoholic hepatitis, mandatory infection screening is required. Which set of evaluations best represents this required workup?
A) Echocardiography, coronary angiography, and cardiac enzymes
B) Blood and urine cultures, chest imaging for pneumonia, and diagnostic paracentesis if ascites is present to exclude spontaneous bacterial peritonitis
C) Upper endoscopy and colonoscopy to exclude gastrointestinal malignancy
D) Thyroid function tests and a fasting lipid panel
E) Electroencephalography and lumbar puncture
ANSWER: B
Rationale:
Because corticosteroids substantially increase infection risk in an already immune-dysregulated cirrhotic population, mandatory pre-treatment screening includes blood and urine cultures, chest imaging for pneumonia, and diagnostic paracentesis if ascites is present to exclude spontaneous bacterial peritonitis; active untreated infection is an absolute contraindication.
Option A: Option A is incorrect because cardiac evaluation does not address the infection risk that governs steroid initiation.
Option C: Option C is incorrect because endoscopic malignancy screening is not the infection workup required before steroids.
Option D: Option D is incorrect because thyroid and lipid testing are unrelated to the pre-steroid infection screen.
Option E: Option E is incorrect because neurological testing is not part of the mandatory infection screening for steroid initiation in alcoholic hepatitis.
15. The Lille model stratifies day-7 corticosteroid response in severe alcoholic hepatitis into three categories. Which set of thresholds is correct?
A) Below 0.45 complete response; 0.45 to 0.75 partial response; above 0.75 non-response
B) Below 0.10 complete response; 0.10 to 0.30 partial response; above 0.30 non-response
C) Below 0.16 non-response; 0.16 to 0.45 complete response; above 0.45 partial response
D) Below 0.16 complete response; 0.16 to below 0.45 partial response in which clinical judgment governs continuation; 0.45 or above non-response warranting discontinuation
A Lille score below 0.16 defines complete response with continuation of the full 28-day course, scores from 0.16 to below 0.45 define a partial-response zone governed by clinical judgment, and a score of 0.45 or greater defines non-response warranting discontinuation of prednisolone.
Option A: Option A is incorrect because it misplaces every cutoff and uses 0.45 and 0.75 boundaries that do not correspond to the validated thresholds.
Option B: Option B is incorrect because the complete-response and non-response cutoffs are not 0.10 and 0.30.
Option C: Option C inverts the meaning of the cutoffs, labeling low scores as non-response when low scores in fact indicate complete response.
Option E: Option E is incorrect because 0.32 and 0.50 are not the validated Lille thresholds; 0.32 is a Maddrey discriminant function cutoff, not a Lille boundary.
16. Which statement most precisely describes how rifaximin lowers ammonia generation and why it is favored over systemic antibiotics in hepatic encephalopathy?
A) It broadly eradicates the entire gut microbiome, leaving the colon sterile
B) It is well absorbed systemically and acts on hepatic urease
C) It suppresses urease-producing ammonia-generating bacteria such as Enterobacteriaceae and Clostridium species within the gut lumen without substantially altering overall microbiome composition at standard doses, with low resistance-selection potential and minimal drug interactions
D) It increases colonic ammonia production to stimulate compensatory hepatic clearance
E) It works by osmotic catharsis rather than any antibacterial effect
ANSWER: C
Rationale:
Rifaximin suppresses urease-producing, ammonia-generating gut bacteria such as Enterobacteriaceae and Clostridium species within the intestinal lumen without substantially altering overall microbiome composition at standard doses, and its non-systemic profile gives it low resistance-selection potential and minimal drug interactions, which is why it is favored over systemic antibiotics.
Option A: Option A is incorrect because rifaximin reduces specific ammonia-generating species rather than sterilizing the colon or eradicating the whole microbiome.
Option B: Option B is incorrect because rifaximin is essentially non-absorbed and does not act on hepatic urease.
Option D: Option D inverts the mechanism, since rifaximin reduces, not increases, colonic ammonia production.
Option E: Option E is incorrect because osmotic catharsis describes lactulose; rifaximin acts through luminal antibacterial activity.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.